Decreased mortality risk due to first acute coronary syndrome in women with postmenopausal hormone therapy use

Show full item record



Permalink

http://hdl.handle.net/10138/229845

Citation

Tuomikoski , P , Salomaa , V , Havulinna , A , Airaksinen , J , Ketonen , M , Koukkunen , H , Ukkola , O , Kesaniemi , Y A , Lyytinen , H , Ylikorkala , O & Mikkola , T S 2016 , ' Decreased mortality risk due to first acute coronary syndrome in women with postmenopausal hormone therapy use ' , Maturitas , vol. 94 , pp. 106-109 . https://doi.org/10.1016/j.maturitas.2016.09.015

Title: Decreased mortality risk due to first acute coronary syndrome in women with postmenopausal hormone therapy use
Author: Tuomikoski, Pauliina; Salomaa, Veikko; Havulinna, Aki; Airaksinen, Juhani; Ketonen, Matti; Koukkunen, Heli; Ukkola, Olavi; Kesaniemi, Y. Antero; Lyytinen, Heli; Ylikorkala, Olavi; Mikkola, Tomi S.
Other contributor: University of Helsinki, Department of Obstetrics and Gynecology
University of Helsinki, Complex Disease Genetics
University of Helsinki, Clinicum
University of Helsinki, Clinicum




Date: 2016-12
Language: eng
Number of pages: 4
Belongs to series: Maturitas
ISSN: 0378-5122
DOI: https://doi.org/10.1016/j.maturitas.2016.09.015
URI: http://hdl.handle.net/10138/229845
Abstract: Objectives: The role of postmenopausal hormone therapy (HT) in the incidence of acute coronary syndrome (ACS) has been studied extensively, but less is known of the impact of HT on the mortality risk due to an ACS. Study design and main outcome measures: We extracted from a population-based ACS register, FINAMI, 7258 postmenopausal women with the first ACS. These data were combined with HT use data from the National Drug Reimbursement Register; 625 patients (9%) had used various HT regimens. The death risks due to ACS before admission to hospital, 2-28, or 29-365 days after the incident ACS were compared between HT users and non-users with logistic regression analyses. Results: In all follow-up time points, the ACS death risks in HT ever-users were smaller compared to non-users. Of women with FIT ever use, 42% died within one year as compared with 52% of non-users (OR 0.62, p <0.001). Most deaths (84%) occurred within 28 days after the ACS, and in this group 36% of women with ever use of FIT (OR 0.73, p = 0.002) and 30% of women with >= 5 year FIT use (OR 0.54, p <0.001) died as compared to 43% of the non-users. Age 60 years at the HT initiation was accompanied with similar reductions in ACS mortality risk. Conclusions: Postmenopausal HT use is accompanied with reduced mortality risk after primary ACS. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
Subject: Estrogen
Myocardial infarction
Case fatality
ACUTE MYOCARDIAL-INFARCTION
PLACEBO-CONTROLLED TRIAL
HEART-RATE-VARIABILITY
REPLACEMENT THERAPY
CARDIOVASCULAR EVENTS
ESTROGEN
DISEASE
MENOPAUSAL
PREVENTION
INSIGHTS
3123 Gynaecology and paediatrics
3121 General medicine, internal medicine and other clinical medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S0378512216302377_main.pdf 397.5Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record